Molecular Cytogenetics Market is valued at USD 2.33 Billion in 2021 and expected to reach USD 4.72 Billion by 2028 with the CAGR of 10.62% over the forecast period.
Global Molecular Cytogenetics Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027– Rising prevalence of cancer and other chronic diseases and increasing need for the development of advanced technologies are some of the major factors expected to boost the growth of Global Molecular Cytogenetic Market.
The molecular cytogenetics combine disciplines molecular biology & cytogenetic and involves the analysis of chromosome structure to help distinguish normal and cancer causing cells. Hence, the molecular cytogenetics encompasses all aspects of chromosome biology and the application of molecular cytogenetic techniques in all areas of biology and medicine including structural and functional organization of the chromosome and nucleus, genome variation, expression and evolution, chromosome abnormalities and genomic variations in medical genetics and tumor genetics. Therefore, the molecular cytogenetics can also be used as a diagnostic tool for congenital syndromes in which the underlying genetic causes of the disease are unknown. Analysis of a patient's chromosome structure can reveal causative changes. The molecular cytogenetics can also be useful in diagnosing and treating various malignancies such as hematological malignancies, brain tumors, and other precursors of cancer. This field is overall focused on studying the evolution of chromosomes more specifically the number structure, function, and origin of chromosome abnormalities.
The molecular cytogenetics techniques are used in karyotyping analysis of G-banded chromosomes other cytogenetics banding techniques as well as molecular cytogenetics such as fluorescent in situ hybridization (FISH) and comparative genomic hybridization (CGH). This specimen requirement is distinctly limiting because for some hospitals, specimens are received in the cutting room already fixed in formalin or the pathologist may prematurely place it in formalin. Thus, to use the karyotyping approach, the pathologist must plan ahead and submit a viable portion of the specimen prior to fixation. In addition, the molecular cytogenetics’ applications in pharmacogenomic are also anticipated to significantly impact market growth as several cytogenetic tools have been successfully used for pharmacogenomic biomarker studies. Effective use of CGH, FISH and sequencing technology in pharmacogenomic is evident by the presence of a substantial number of published articles demonstrating the role of cytogenetic techniques in pharmacogenomic testing.
Global Molecular Cytogenetics Market report is segmented on the basis of product, application, and by regional & country level. Based on type, global molecular cytogenetic market is classified as the in-situ, FISH and comparative genomic hybridization. Based upon application, global molecular cytogenetics is classified into research labs and institutes.
The regions covered in this Molecular Cytogenetics market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Molecular Cytogenetics is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Some major key players for Global Molecular Cytogenetic Market are
The rapidly increasing incidences of genetic disorders and cancer related growth in mortality per year have significantly driven the market growth. Continuous rise in new cancer cases has emphasized the need for development of advanced technologies for a comprehensive understanding of cancer at a genomic level. According to World Organization (WHO) in 2040, the global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths simply due to the growth and aging of the population. In addition, increasing adoption of various cytogenetic tools for pharmacogenomic biomarker studies and increasing technological advancements in Fluorescence in Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) CGH techniques are also expected to boost the growth of the global market. However, less availability of skilled professionals across the globe and high cost associated with the molecular cytogenetic techniques are some of the challenging factors that may hamper the growth of target market.
In spite of that, ongoing technological advancements in CGH and FISH, with respect to resolution and specificity, have augmented the application scope of cytogenetic tools in basic research and molecular diagnostics. These advancements have successfully overcome the limitations of conventional cytogenetic analysis. In addition, increasing penetration of various molecular cytogenetic products such as consumables, software and services, instruments, and reagents and kits across the globe is one of the key factors projected to propel growth of the global molecular cytogenetic market. In the current scenario, CGH and FISH techniques are widely adopted across various applications such as diagnostics, research activities, and medicine development can provide various opportunities for the further growth of the market. Various advantages CGH and FISH techniques offer over conventional techniques have allowed these segments to account for a major share in the market. CGH captured the dominant share owing to its vital role in comprehensive cancer studies. This technique has also eliminated the need for metaphase chromosomes, which results in enhanced resolution.
The global molecular cytogenetics market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. The North America molecular cytogenetics market is expected to contribute for the largest market share in terms of revenue in the global market owing to the high presence of research and academic institutes and clinical research laboratories in the countries such as Canada and U.S. in this region. According to World Organization (WHO) in 2018, The highest incidence rates are expected in Northern America, the Colorectal cancer is the third most common cancer in men and the second in women are Worldwide, an estimated 1.8 million cases of colorectal cancer about 880,800 deaths from colorectal cancer will occur in worldwide accounting for 9% of all cancer deaths. In addition, the presence of effective regulatory framework for the regulation of genetic tests has significantly propelled the regional market. According to World Organization (WHO) in U.S, the estimated 11,060 new cancer cases will be diagnosed among children ages 0 to 14 years in the U.S. in 2019.
The Asia Pacific is projected to register the fastest growth in the global market followed by the market in Europe. The continuous GDP growth in countries such as China and India led to enhance consumer buying power and drive regional growth market, owing to high healthcare expenditure, rising number of scientific researches, and high awareness about advanced therapies and diagnostics in many countries in these regions. According to World Organization (WHO) 2019; in Asia Pacific, the estimated 13,980 ovarian cancer deaths will occur in ovarian cancer accounts for 5% of cancer deaths among women, more than any other gynecologic cancer. Ongoing workshops and interventions in Asia Pacific pertaining to current trends and developments in human genetics and disease management are driving the Asian market. According to the International Agency for Research on Cancer (IARC) in Asia Pacific 2018, the estimates will be 17.0 million new cancer cases in worldwide, of which 657,000 will occur in countries with a low HDI, 2.8 million in medium-HDI countries, 6.4 million in high-HDI countries, and 7.2 million in very high-HDI countries. These workshops are aimed at improving awareness about the significance of advanced diagnostics and therapies among the population.
March 3rd, 2020: Agilent technologies unveiled three new microarrays to support pre- and postnatal research by cytogenetic laboratories. The genetisure cyto microarrays feature updated and clinically relevant content from respected databases, according to the firm. Additionally, the microarray probes yield high-resolution detection of copy number variations and copy-neutral loss of heterozygosis associated with developmental delays, neuropsychiatric disorders, intellectual disability, congenital anomalies or unexplained dimorphic features in constitutional DNA samples. Besides, the new arrays utilize different specifications depending on if they are being used for pre- postnatal research to focus on clinically relevant regions. The arrays can achieve up to exon-level resolution according to the firm.
|2015 - 2020
|2021 - 2027
|Market Size in 2021:
|USD 2.33 Billion
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 4.72 Billion
|Tables, Charts & Figures:
|Abbott Laboratories, Agilent Technologies, Applied Spectral Imaging, Bio-Rad Laboratories, Danaher, Illumina, Oxford Gene Technology, PerkinElmer, F. Hoffmann-La Roche, Thermo Fisher Scientific, others.
|By Type, By Application
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®